2024
Detection of hepatocellular carcinoma methylation markers in salivary DNA
Mezzacappa C, Wang Z, Lu L, Risch H, Taddei T, Yu H. Detection of hepatocellular carcinoma methylation markers in salivary DNA. Bioscience Reports 2024, 44: bsr20232063. PMID: 38457142, PMCID: PMC10958141, DOI: 10.1042/bsr20232063.Peer-Reviewed Original ResearchHepatocellular carcinoma screeningCase patientsHepatocellular carcinomaControl subjectsDiagnosis of hepatocellular carcinomaAssociated with hepatocellular carcinomaScreening testSalivary DNASaliva-based testCpG sitesStudy of risk factorsSalivary DNA methylationDNA methylationViral hepatitisCirculating DNAAlterations to DNA methylationRisk factorsMethylation markersPatientsRegulation of cell cycle progressionBlood samplesCell cycle progressionAffected individualsAlternative to blood samplingMultiple comparisons
2010
ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study
Risch HA, Yu H, Lu L, Kidd MS. ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study. Journal Of The National Cancer Institute 2010, 102: 502-505. PMID: 20181960, PMCID: PMC2902822, DOI: 10.1093/jnci/djq007.Peer-Reviewed Original ResearchMeSH KeywordsABO Blood-Group SystemAdultAgedAged, 80 and overAntibodies, BacterialAntigens, BacterialBacterial ProteinsCase-Control StudiesConfounding Factors, EpidemiologicConnecticutEnzyme-Linked Immunosorbent AssayFemaleHelicobacter InfectionsHelicobacter pyloriHumansIncidenceMaleMiddle AgedOdds RatioPancreatic NeoplasmsConceptsNon-O blood typeH pylori seropositivityCase-control studyPancreatic cancerPylori seropositivityABO blood groupEnzyme-linked immunosorbent assayBlood typeBlood groupPopulation-based case-control studyNon-O blood groupControl subjects frequencyH pylori colonizationVirulence protein CagAHelicobacter pylori seropositivityPancreatic cancer riskO blood typeRandom digit dialingCagA seropositivityCase patientsH pyloriControl subjectsRisk factorsPylori colonizationCancer risk
2000
Joint Effect of Insulin-Like Growth Factors and Mutagen Sensitivity in Lung Cancer Risk
Wu X, Yu H, Amos C, Hong W, Spitz M. Joint Effect of Insulin-Like Growth Factors and Mutagen Sensitivity in Lung Cancer Risk. Journal Of The National Cancer Institute 2000, 92: 737-743. PMID: 10793110, DOI: 10.1093/jnci/92.9.737.Peer-Reviewed Original ResearchMeSH Keywords7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxideBleomycinCase-Control StudiesChromosome AberrationsData Interpretation, StatisticalFemaleHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IILung NeoplasmsLymphocytesMaleMutagenicity TestsMutagensRisk FactorsSomatomedinsConceptsIGF-binding protein-3Lung cancer riskLung cancerCancer riskHigher IGFOdds ratioBPDE sensitivityInsulin-like growth factorMutagen sensitivityLevels of IGFPeripheral blood lymphocyte culturesLung cancer patientsSpecific histologic typesBleomycin sensitivityBlood lymphocyte culturesProliferation potentialHistologic typeTumor stageCancer patientsControl subjectsIGF-IIRisk factorsGenetic instabilityHumoral factorsLymphocyte cultures
1999
Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis
Yu H, Spitz M, Mistry J, Gu J, Hong W, Wu X. Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis. Journal Of The National Cancer Institute 1999, 91: 151-156. PMID: 9923856, DOI: 10.1093/jnci/91.2.151.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorLung cancer riskHigher plasma levelsPlasma levelsIGFBP-3Lung cancerControl subjectsIGF-IICancer riskOdds ratioLevels of IGFIGFBP-3 plasma levelsGrowth factorIGFBP-3 levelsPlasma IGFBP-3Primary lung cancerIGF-binding proteinsCase-control studyLung cancer developmentCase-control analysisEnzyme-linked immunosorbentPossible causal roleIGF variablesCase patientsConsecutive patients